leisure time -WSS

leisure time

author：focus 2025-09-07 11:09:31 - browse：563

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Scientists grapple with ethics of stem cell research

WSS

Hormonal contraceptives don’t actually treat endometriosis

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

'CMA Fest' 2023: How to watch, who is performing and more

How a Boston hospital is priming medical residents to use GPT

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

In rare move, senator releases unverified FBI source report alleging Biden bribe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The stock market has soared this year, but will it last? Experts weigh in

Tori Bowie and the unacceptable rates of Black maternal death

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Tori Bowie and the unacceptable rates of Black maternal death

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Duchenne breakthrough therapy leaves behind pioneering families

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

hotspot

White House Covid adviser calls on docs to combat misinformation

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Sanders wants to replace patents with prizes for drug inventions

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

'A game

How a Boston hospital is priming medical residents to use GPT

knowledge

focus

focus

hotspot